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A previous study shows that Hsp60 not only interacts with, but also activates human hepatitis B virus polymerase, HBV Pol
(S. G. Park and G. Jung, 2001, J. Virol. 75, 6962–6968). To provide a more detailed analysis of the relationship between the two
proteins, (i) the binding sites on human HBV Pol for Hsp60 and (ii) the effect of pregenomic RNA on human HBV Pol-Hsp60
binding were analyzed. The binding sites on human HBV Pol were mapped with several deletion mutant proteins of the Pol
expressed in insect cells by using recombinant baculovirus. Immunoprecipitation of each deletion mutant protein by M2
beads showed that binding of Hsp60 to human HBV Pol requires two minimal sites on human HBV Pol: amino acids 1 to 199
(TP) and amino acids 680 to 842 (RH). Human HBV Pol was also shown to bind to Hsp60 in HepG2 cells, the host cell line
for human HBV. In addition, Hsp60 binding to the Pol was found to be dispensable to pregenomic RNA binding to human HBVINTRODUCTION
Human hepatitis B virus (HBV), a member of the hep-
adnavirus family, is an enveloped, partially double-
stranded DNA virus (for reviews, see Ganem and Var-
mus, 1987). It is also associated with the development of
hepatocellular carcinoma and liver cirrhosis (Beasley et
al., 1981). After the viral infection of hepatocytes, viral
DNA is converted to covalently closed circular DNA
(cccDNA) in the nucleus (Kann et al., 1999; Mason et al.,
1983; Seeger and Mason, 1996; Tagawa et al., 1986)
through which four unspliced transcripts are produced
(for reviews, see Ganem and Varmus, 1987). This viral
genome is replicated through reverse transcription of
pregenomic RNA. Pregenomic RNA is one of the four
unspliced transcripts mentioned above that encodes for
human HBV polymerase (HBV Pol) (Huang and Summers,
1991). The reverse transcription is initiated by priming
through the 63rd tyrosine residue of human HBV Pol,
which provides the hydroxyl group needed for primer
synthesis (Zoulim and Seeger, 1994). During the priming,
three to four nucleotides are synthesized by human HBV
Pol at the bulge region of the epsilon stem-loop region in
pregenomic RNA. The synthesized oligonucleotides
transfer to the direct repeat (DR) 1 region and functions
as primers for ()-stranded DNA synthesis (Seeger et al.,
1986). During DNA synthesis, the RNase H domain,
which is in the carboxyl terminal region of human HBV
Pol, hydrolyzes the RNA template, in this case pre-
genomic RNA (Radziwill et al., 1990). After completion of
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116()-stranded DNA synthesis, the ()-stranded DNA is
synthesized by the Pol using the ()-stranded DNA as
the template. During this process, unhydrolyzed pre-
genomic RNA is utilized as the primer for synthesis of
()-stranded DNA (Will et al., 1987).
In the initiation of HBV genome replication, the inter-
action between HBV Pol and the epsilon stem-loop re-
gion in pregenomic RNA is essential. It has been well
known that this interaction is critical to pregenomic RNA
packaging and the above priming process (Pollack and
Ganem, 1993). This interaction is also known to have
cis-preference, which is supposed to be a cotransla-
tional event (Junker-Niepmann et al., 1990). In in vitro
translation systems, it has been reported that binding
between duck HBV Pol and the epsilon stem-loop region
is facilitated by the Hsp90 complex which includes
Hsp90, p23, Hsp70, and so on (Hu and Seeger, 1996; Hu
et al., 1997). Recent studies show that duck HBV Pol
expressed in the Escherichia coli system shows in vitro
priming activity only if the Pol is assisted by Hsp90 (Hu
and Anselmo, 2000). In addition, it has been suggested
that Hsp90 binding for duck HBV Pol may have induced
conformational changes in the Pol, which facilitates the
binding of duck HBV Pol to the epsilon stem-loop region
(Hu and Seeger, 1996; Hu et al., 1997). It was also shown
that Hsp90 could stabilize duck HBV Pol activity after
priming (Hu and Anselmo, 2000). Another chaperone,
Hsp60, has also been identified as a human HBV Pol
binding protein. It functions as an activating factor for
human HBV Pol, which was shown through an analysis
of human HBV Pol expressed in insect cells using thePol. Overall, this article infers that Hsp60 activates human H
the Pol binding to Hsp60 does not require pregenomic RN
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recombinant baculovirus system (Park and Jung, 2001).
Although Hsp60 has been well known as a chaperonin inBV Po
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mitochondria, recent studies indicate that Hsp60 is also
able to function as an activating factor. For example,
pro-caspase-3 and the prion protein are activated by
Hsp60 (Edenhofer et al., 1996; Samali et al., 1999; Xan-
thoudakis et al., 1999).
The biochemical and functional studies of human HBV
Pol are made possible by the high expression level of
human HBV Pol in the recombinant baculovirus system
(Lanford et al., 1995, 1997, 1999). The human HBV Pol
obtained in the insect cell system is active in in vitro
priming (Lanford et al., 1995) from which the fact that the
insect cells provided the factors required for human HBV
Pol maturation can be inferred. Formerly, Hsp60 was
shown to bind to and function as an activating factor for
human HBV Pol (Park and Jung, 2001). In this article, a
more detailed interaction between human HBV Pol and
Hsp60 was sought. The binding sites on human HBV Pol
for Hsp60 were identified to be at the TP (amino acids
1–199) and the RH (amino acids 680–842) domains of
human HBV Pol. These sites were suggested to be mod-
ulation sites. Also through this experiment, the binding
between human HBV Pol and the Pol binding to Hsp60
does not require pregenomic RNA, although Hsp60 af-
fected human HBV Pol priming activity.
RESULTS
Expression of human HBV Pol deletion mutant
proteins in insect cells
A previous study indicates that Hsp60 interacts with
human HBV Pol and this interaction is required for hu-
man HBV Pol activation (Park and Jung, 2001). The acti-
vation of human HBV Pol may be modulated at its binding
site for Hsp60. To analyze the binding sites in human
HBV Pol, we made constructs for expression of human
HBV Pol deletion mutant proteins: amino terminal dele-
tion, internal deletion, and carboxyl terminal deletion
mutant proteins. Each recombinant baculovirus was gen-
erated by the BAC-TO-BAC system as shown under Ma-
terials and Methods. Each deletion mutant protein was
expressed in Sf-9 cells and immunoprecipitated by M2
agarose beads. These immunoprecipitated proteins
were analyzed by sodium dodecyl sulfate–polyacrylam-
ide gel electrophoresis (SDS–PAGE) and Coomassie
blue staining. Figure 1A shows that each deletion mutant
protein immunoprecipitated by M2 agarose beads ap-
pears to be in the expected apparent molecular weight.
To confirm that proteins in the bands were the correct
FLAG-fused deletion mutant proteins, immunoblot anal-
yses were performed with the M2 monoclonal antibod-
ies. Each purified band was immunostained by the M2
monoclonal antibodies (Fig. 1B), indicating that the pro-
teins were successfully expressed in the insect cells. In
the case of FPol1-199E, the molecular weight is very
similar to the light chain of the M2 monoclonal antibody
heavily stained with anti-mouse secondary antibodies
(Fig. 1B, lane 4). This resulted in overlapping of the two
bands.
Hsp60 binds to the TP and the RH domains of human
HBV Pol but one site is enough for binding of Hsp60
to human HBV Pol
Each deletion mutant protein of human HBV Pol was
expressed in Sf-9 cells. The expressed proteins were
immunoprecipitated by M2 agarose beads and analyzed
by SDS–PAGE and Coomassie blue staining. In the Coo-
massie blue stained gel, we found that the Hsp60 band
FIG. 1. Confirmation of each deletion mutant protein of human HBV Pol. The expressed proteins were immunoprecipitated by M2 beads as
described under Materials and Methods. (A) Each purified protein sample was analyzed on SDS–PAGE and Coomassie blue staining. (B) To confirm
that each protein bands was exact FLAG tagged-recombinant deletion mutant protein of human HBV Pol, the immunoblot analysis was performed
with M2 monoclonal antibodies. , each expressed deletion mutant of human HBV Pol; ˜, Hsp60; Š, heavy chains of M2 antibodies; , light
chains of M2 antibodies.
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did not appear in some lanes of the deletion mutant
proteins (Fig. 1A). Human HBV Pol of these bands had
deletions in both amino acids 1 to 177 and amino acids
680 to 842. In other words, the mutant proteins that did
not contain the two regions did not bind to Hsp60. These
binding regions represent the TP (amino acids 1–199)
and the RH (amino acids 680–842) domains of human
HBV Pol. To confirm that each copurified Hsp60 band
was in fact Hsp60, an immunoblot analysis was per-
formed using anti-Hsp60 polyclonal antibodies (Fig. 2A).
This analysis showed that the bands were in fact Hsp60
(Fig. 2A). Levels of Hsp60 were almost same in total
extract of each cell (Fig. 2B) and this indicates that the
above results were not caused by variation of Hsp60
level in cells. Conclusively, binding of Hsp60 to human
HBV Pol requires two minimal regions of human HBV Pol,
TP (amino acids 1–199) and RH (amino acids 680–842),
but one of the two binding regions is enough for binding
of human HBV Pol to Hsp60 (Fig. 2C).
Human HBV Pol expressed in HepG2 cells, the host
cell line, also binds to Hsp60
To test whether human HBV Pol binds to Hsp60 in
mammalian cells especially in hepatocytes, a MBP (40-
kDa) fused-human HBV Pol protein was expressed in the
hepatocyte cell line, HepG2 cells (Fig. 3A). Because the
expression level of the Pol in HepG2 cells is low, immu-
noblot analyses with anti-MBP and anti-Hsp60 antibod-
ies were performed. The expressed MBP fused–human
HBV Pol (MBP–Pol) complex was immunoprecipitated
with anti-MBP monoclonal antibodies and analyzed by
an immunoblot analysis using anti-MBP polyclonal anti-
bodies. In the immunoblot analysis, bands of smaller
molecular weight than the full-length MBP–Pol complex
(130-kDa) appeared to be immunostained (Fig. 3A).
These bands may be bands of MBP–Pol degradation
products because these bands do not appear in the
negative control and also the molecular weight is smaller
than full-length human HBV Pol molecular weight. The
negative control was prepared by transfection of pCMV/
MBP into HepG2 cells by the same methods of pCMV/
MBP–Pol transfection. Immunoblot analysis with anti-
Hsp60 polyclonal antibodies was performed with immu-
noprecipitated MBP–Pol. Figure 3B indicates that Hsp60
is present in the MBP–Pol fraction, but not in the negative
control. This result strongly supports the binding of hu-
man HBV Pol with Hsp60 in mammalian host cells.
FIG. 2. Analysis of the Hsp60 binding site on human HBV Pol. (A) The produced mutant proteins were immunoprecipitated by M2 beads and
separated on SDS–PAGE (10.5–11.5% gels). The separated proteins were electroblotted into a PVDF membrane and the blots were analyzed by
anti-Hsp60 polyclonal antibodies. (B) To confirm that the Hsp60 level of each infected cell was not different from each other, the soluble crude extracts
of the Sf-9 cells, which were infected by each recombinant baculovirus, were analyzed by immunoblot analysis with anti-Hsp60 polyclonal antibodies.
(C) Binding sites of human HBV Pol for Hsp60. Hsp60 binds to TP and RH domains of the Pol and one of the two sites enough for the binding.
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Human HBV Pol-Hsp60 binding does not require
human HBV Pol-pregenomic RNA binding
Previous reports show that human HBV Pol, expressed
in insect cells using the recombinant baculovirus expres-
sion system, forms a complex with Hsp60 (Park and Jung,
2001) and with pregenomic RNA (Lanford et al., 1995). To
test the effect of pregenomic RNA on human HBV Pol–
Hsp60 binding, first, we constructed FPolE in which the
3 nontranslated region containing the epsilon stem-loop
region was deleted from FPolE (Fig. 4). Immunoprecipi-
tation of this construct by M2 beads showed that Hsp60
still binds with human HBV Pol though the epsilon stem-
loop region is absent in the human HBV Pol complex
(Fig. 5A). Additionally, the amount of Hsp60 bound to
FPolE was observed to be constant compared to the
amount of Hsp60 bound to FPolE (Fig. 5A, left panel).
From the immunoblot analysis, human HBV Pol binding
to the epsilon stem-loop region in pregenomic RNA is
observed to have no effect on human HBV Pol-Hsp60
binding, too (Fig. 5A, right panel). However, there is still
a possibility that the presence of other regions of pre-
genomic RNA can affect human HBV Pol-Hsp60 binding.
Figure 5B shows that Hsp60 still binds with human HBV
Pol though treated with three types of nucleases: RNase
A, DNase I, and micrococcal nuclease. Moreover, the
amount of Hsp60 bound to human HBV Pol did not
decrease compared to the control that was not treated
with the nucleases (Fig. 5B). The results of nuclease
treatments indicate that Hsp60 binding for human HBV
Pol is not mediated by any nucleic acids including the
pregenomic RNA. The above results indicate that human
HBV Pol–Hsp60 binding does not require epsilon RNA
binding to human HBV Pol.
DISCUSSION
A previous study shows that Hsp60 binds to human
HBV Pol and that this process is important for Pol acti-
vation in in vitro conditions (Park and Jung, 2001). Hsp60
is a new host factor for human HBV Pol activation and
this may be helpful for understanding the mechanism of
human HBV DNA replication. Generally, Hsp60 is abun-
dant in cells and functions as a chaperone assisting in
protein folding (Bukau and Horwich, 1998). Hsp60 is
mainly localized in the mitochondria matrix, but the pro-
tein can be found in other regions such as the cell
surface and the cytosol (Itoh et al., 1995, 1999; Soltys and
Gupta, 1996, 1997). In the mitochondria matrix, Hsp60
assists the folding of proteins imported into the mito-
chondria matrix (Bukau and Horwich, 1998). In extra
mitochondria regions, it has been reported that Hsp60
functions as an autoantigen on the cell surface (Itoh et
al., 1995), but its functions in the cytosol have not yet
been discovered. In the case of yeast DNA Pol, Hsp60
was copurified with this Pol and was found to function as
FIG. 4. Constructions. (A) The pFPolE construction was previously
described (Park and Jung, 2001). In short, the transfer-vector pFPolE
was cloned by an insertion of a fragment downstream of the polyhedrin
promotor. The fragment contains human HBV Pol ORF, the epsilon
stem-loop region, and 3 NTR containing DR2, DR1. This epsilon stem-
loop region is the template in human HBV Pol priming. The transfer-
vector pFPolE was constructed through deletion of 3 NTR. As a
negative control for the RNA binding assay, pEpsilon was constructed
by insertion of the 3 NTR into pFASTBAC. Each recombinant baculo-
virus (vFPolE, vFPolE, and vEpsilon) was generated by the BAC-TO-
BAC system. Transfer vectors for expression of deletion mutant pro-
teins of human HBV Pol were constructed through PCR-mediated
mutagenesis and recombinant baculoviruses were generated as de-
scribed under Materials and Methods. The proteins were expressed in
Sf-9 cells using each generated recombinant baculovirus. (B) To ex-
press human HBV Pol in HepG2 cells, pCMV/MBP Pol was constructed.
The process for its construction is described in our previous study (Cho
et al., 2000a). As the negative control, pCMV/MBP was constructed by
the insertion of MBP ORF from pMal-c2 into pCMV vector.
FIG. 3. Human HBV Pol expressed in HepG2 cells also binds to
Hsp60. The plasmids, pCMV/MBP-Pol (lane 2), containing MBP fused-
human HBV pol downstream of the CMV promoter were transfected
into HepG2 cells by calcium phosphate transfection method. Two days
after the transfection, the transfected cells were harvested, lysed, and
subjected to immunoprecipitation with anti-MBP monoclonal antibod-
ies as previously described (Cho et al., 2000a). (A) Half of the immu-
noprecipitated protein of each sample was analyzed by an immunoblot
analysis with anti-MBP polyclonal antibodies (Cho et al., 2000a). (B) The
remaining half of each sample was analyzed by an immunoblot anal-
ysis with anti-Hsp60 polyclonal antibodies.
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stimulating factor I (SFI) (Brown et al., 1990; Smiley et al.,
1992). As indicated above, Hsp60 is localized in various
regions in cells and has diverse functions as a chaper-
one, an autoantigen, a protein activation factor, and so
on.
In this article, we analyzed in more detail the binding
property of Hsp60 for human HBV Pol. The recombinant
baculovirus system was used to express human HBV Pol
in insect cells because expression of human HBV Pol in
hepatocytes is very difficult and sequences of Hsp60 are
highly conserved between eukaryotes. Binding site anal-
ysis by using many deletion mutant proteins of human
HBV Pol showed that binding of Hsp60 to human HBV Pol
requires two minimal sites on human HBV Pol: amino
acids 1 to 199 (TP) and amino acids 680 to 842 (RH). In
addition, one of the two binding sites was found to be
sufficient for binding of Hsp60 to human HBV Pol. If
binding was caused by overexpression of the proteins,
all of the Pol deletion constructs must have bound to
Hsp60. These results indicate that the bindings are spe-
cific. Therefore, the results of binding site analysis indi-
cate a possibility that Hsp60 activates the human HBV
Pol by binding to TP and RH domains of the Pol. The
binding between Hsp60 and the TP and the RH regions
of the human HBV Pol is interesting. Recently, another of
our studies showed that human HBV Pol also binds to
Hsp90 (Cho et al., 2000a,b) and that this binding is
important for showing in vitro priming activity (data not
shown). It has been reported that Hsp90 binds to the TP
and the RT domains in both human and duck HBV Pol
(Cho et al., 2000a; Hu and Anselmo, 2000). Of the two
binding sites, the TP domain overlaps with Hsp60 bind-
ing site. To solve the relationship between the two chap-
erones, we needed to test whether their relationship is
temporal or spatial. A recent report of duck HBV Pol
shows that GroEL, a protein in the Hsp60 family in E. coli,
also binds to the Pol and it has been predicted that
GroEL assists in the Pol maturation (Hu and Anselmo,
2000). This study suggests that binding of GroEL to duck
HBV Pol is important for in vitro priming activity before
the binding of Hsp90 (Hu and Anselmo, 2000), providing
the possibility that Hsp60 may interact with human HBV
Pol before it interacts with Hsp90. However, the role of
Hsp60 on human HBV Pol is still uncertain except for its
role in activation and the binding sites of Hsp60 on
human HBV Pol.
During priming, binding of human HBV Pol on pre-
genomic RNA containing the epsilon stem-loop region is
essential for synthesis of ()-stranded DNA of the hu-
man HBV genome. In the case of duck HBV Pol, binding
of HBV Pol for the epsilon stem-loop region is facilitated
by the Hsp90 complex (Hu and Seeger, 1996; Hu et al.,
1997). To test the relationship between pregenomic RNA
and Hsp60, the following experiments were performed.
An analysis of whether pregenomic RNA binding to hu-
man HBV Pol influences for human HBV Pol-Hsp60 bind-
ing or not, pFPolE was constructed and nucleases
were treated. In addition, Hsp60 also binds to FPolE
FIG. 5. Human HBV Pol-Hsp60 binding does not require human HBV Pol-pregenomic RNA binding. (A) Two kinds of human HBV Pol, FPolE (lane
1) and FPolE (lane 2), were expressed in insect cells by infection of Sf-9 cells with each recombinant baculovirus. The expressed proteins were
immunoprecipitated by M2 beads as described under Materials and Methods. The precipitated proteins were analyzed by SDS–PAGE and Silver
staining (left). Additionally, the proteins were analyzed by an immunoblot analysis with anti-Hsp60 polyclonal antibodies (right). (B) To exclude the
effects of any other nucleic acids for human HBV Pol-Hsp60 binding, three nucleases (RNaseA, DNaseI, and micrococcal nuclease) were treated to
purified human HBV Pol bound to the M2 beads. After treatment, the M2 beads were serially washed with TNG, TNG  1 M NaCl, and TNG. The
proteins were eluted by and 1 SDS sample buffer and analyzed by immunoblot analysis with anti-Hsp60 polyclonal antibodies. Only the buffer for
each nuclease treatment was added to the purified human HBV Pol as a negative control for each nuclease treatment. The B represents the buffer.
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that does not contain the epsilon stem-loop region. Nu-
clease treatments also did not affect the binding be-
tween human HBV Pol and Hsp60. These results show
that Hsp60 binding to human HBV Pol does not require
epsilon RNA binding to human HBV Pol.
In this article, we found that Hsp60 binds to both the
TP and the RH domains of human HBV Pol, which may be
modulation sites for Pol activation by Hsp60. Moreover,
this binding is dispensable to pregenomic RNA binding
to human HBV Pol. Recently, it has been reported that
Hsp60 also participates in the activation of human im-
munodeficiency virus type 1 integrase (Parissi et al.,
2001). Therefore, this article and our data indicate that
Hsp60 plays a role in activation of viral enzymes. The
above data provide a more in-depth analysis of the re-
lationship between human HBV Pol and Hsp60. These
results may helpful for further analysis of human HBV
Pol–Hsp60 functional interaction.
MATERIALS AND METHODS
Plasmid construction
The construction of baculovirus transfer vector pFPolE
is as previously described (Park and Jung, 2001). In short,
the amino-terminal region of the human HBV Pol open
reading frame (ORF) fused with a FLAG tag (Met-Asp-
Tyr-Lys-Asp-Asp-Asp-Asp-Lys-Leu) was generated by
using PCR-mediated mutagenesis. Then, this fragment
was cloned into a pFASTBAC vector (Park and Jung,
2001). The remaining ORF including the carboxyl terminal
region and the 3 nontranslated region (NTR) also was
cloned into the above vector (Fig. 4). In the case of the
pFPolE construct, a fragment starting from the EcoRI
site which is behind the stop codon of human HBV Pol
ORF to SalI site which is behind the poly(A) signal se-
quence in pFPolE was removed by enzymatic digestion.
The overhanging fragments of the remaining pFPolE con-
struct were filled in and then the newly formed blunt ends
self-ligated (Fig. 4). In the case of the pEpsilon construct,
the fragment including amino acid 346 (XhoI site) of the
Pol up to the poly(A) signal sequence (SalI site) was
inserted into pFASTBAC (Fig. 4). For deletion mutant
protein expressions of human HBV Pol, the deletion
fragments of human HBV Pol were generated through
PCR-mediated mutagenesis (Fig. 4). In each case, a
deletion fragment was amplified with forward primers
fused to the FLAG tag sequence at the 5 ends and
reverse primers containing EcoRI restriction site and
termination codon at the 5 ends. For each construct, the
starting and terminating amino acids were given, fol-
lowed by the construct name (e.g., FPol177-679E stands
for the FLAG-internal deletion construct with an amino
terminus that begins at amino acid 177 and a carboxyl
terminus that ends at amino acid 679; the “E” represents
the epsilon stem-loop region). For expression in HepG2
cells, we used previously constructed pCMV/MBP-Pol
(Cho et al., 2000a). For this construct, MBP fused-human
HBV Pol ORF was cloned downstream of the CMV pro-
moter in pCMV vector. The SV40 poly(A) signal sequence
follows the human HBV Pol ORF. A pCMV/MBP was
constructed by the insertion of MBP ORF into the above
pCMV vector. MBP ORF was obtained from pMAL-c2
plasmids (New England BioLabs, Inc.). The methods of
expression and immunoprecipitation of MBP fused-hu-
man HBV Pol were described in a previous study (Cho et
al., 2000a).
Cells and infections
Spodoptera frugiperda Sf-9 cell line was maintained in
TNM-FH (Sigma) supplemented with 5% certified fetal
bovine serum (Life Technology, Inc.). Recombinant bacu-
loviruses were generated with the plasmid constructed
above using the BAC-TO-BAC system (Life Technology,
Inc.). For protein production, when the Sf-9 cells reached
about 70% confluence, the recombinant baculoviruses
(multiplicity of infection, 2 to 10) were added to the
medium in which the cells were cultured and incubated
for 2 h at 22°C. The medium was renewed with fresh
medium and virus-infected cells were incubated at 27°C.
Two days later, the infected cells were harvested and
stored at 70°C until use. The HepG2 cells, the cell line
for human hepatocytes, were cultured in MEM (Life
Technology, Inc.) supplemented with 10% qualified fetal
bovine serum (Life Technology, Inc.).
Immunoprecipitation of human HBV Pol using M2
beads
As previously indicated, Sf-9 cells were infected with
each recombinant baculovirus for 2 days (Park and Jung,
2001). Then the cells were lysed with 1 ml lysis buffer per
1  107 cells on ice for 15 min. The lysis buffer contains
1 mM EDTA, 5 mM dithiothreitol, 0.5% NP-40, 1 mM
phenylmethylsulfonyl fluoride, 100 M leupeptin, and 50
U recombinant RNAsin (Promega) per ml added to phos-
phate-buffered saline (PBS). The extracts were cleared
by centrifugation at 30,000 g for 15 min at 4°C. The
cleared extracts were incubated with M2 agarose beads
(Sigma) for 2 h on ice and the beads were washed
sequentially once with 1 ml TNG (100 mM Tris–Cl, pH 7.5,
30 mM NaCl, and 10% glycerol), twice with 1 ml TNG with
1 M NaCl, and once again with 1 ml TNG. It is critical for
the washing step with TNG 1 M NaCl to be longer than
5 min. The bound proteins were eluted once with 1
SDS sample buffer. The purified proteins were frozen at
70°C until use. As otherwise indicated, Sf-9 cells for
production of human HBV Pol were infected by vFPolE.
Immunoblot analysis
Each protein sample was electrophoresed on its ap-
propriate percentage SDS–PAGE and subsequently
transferred to a polyvinylidene difluoride (PVDF) mem-
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brane in a solution of 25 mM Tris–Cl, pH 8.3, 192 mM
glycine, and 20% methanol. Each blot was incubated with
the appropriate antibodies: anti-Hsp60 goat polyclonal
N-20 antibody (Santa Cruz Biotechnology, Inc.), anti-MBP
polyclonal antibody (Cho et al., 2000a), and M2 mono-
clonal antibody (Sigma), each at dilution levels recom-
mended by the manufacturers. The incubation steps
were performed as described previously (Towbin et al.,
1979). The antibodies were detected by chemilumines-
cence (ECL System, Amersham Pharmacia Biotech).
Treatment of nuclease (RNase A, DNase I,
micrococcal nuclease)
Following the purification of the FLAG-epitope fused
human HBV Pol through the above purification step, M2
beads were downed by centrifugation at 700 g for 3 min
and the supernatant was removed. After removal of the
residual solution, 1 g/l RNase A (Sigma) in TNG, 1
U/l DNase I (Promega) in DNase I buffer (40 mM Tris–
Cl, pH 7.4, 6 mM MgCl2, and 2 mM CaCl2), or 3 U/l
micrococcal nuclease (MBI Fermentas) in nuclease
buffer (50 mM Tris–Cl, pH 8.8, 50 mM NaCl, and 5 mM
CaCl2) was added and the solution was incubated in a
water bath of 37°C. This solution was periodically agi-
tated for resuspension of the M2 beads. After incubation,
the M2 beads bound to the proteins were sequentially
washed once with TNG, twice with TNG and 1 M NaCl,
and a last time with TNG. The proteins bound to the M2
beads were eluted with 1 SDS sample buffer and
analyzed by an immunoblot with anti-Hsp60 polyclonal
antibodies (Santa Cruz Biotechnology, Inc.).
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